Literature DB >> 9346731

Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis.

R Shrestha1, C McKinley, R Showalter, K Wilner, L Marsano, B Vivian, G T Everson.   

Abstract

Some patients with early-stage cirrhosis preserve hepatic function, whereas others have little hepatic reserve and rapidly deteriorate. The aim of this study was to use quantitative tests of liver function (QLFTs) to define the degree of functional hepatic impairment in patients with early-stage cirrhosis (Child-Pugh score 5-7) and to determine whether the tests predicted subsequent hepatic decompensation. We recruited 10 cirrhotic (Cr) patients and 10 healthy controls (NI), who were well matched for race, age, weight, and gender. Clearances of caffeine (CF) and antipyrine (AP) after oral administration were measured from timed samples of saliva. The clearance of cholate (CA) was measured from serum samples obtained after simultaneous oral ([2,2,4,4-2H]CA) and intravenous ([24-13C]CA) administration. CA shunt was calculated as (Cl i.v./Clo x 100%). CF elimination rate (Cr v NI, mean +/- SD: 0.03 +/- 0.02 v 0.075 +/- 0.018 h-1, P < .0005) and AP clearance (24 +/- 16 v 40 +/- 7 mL/minute, P < .02) were reduced in Cr patients. CA shunt was increased in Cr patients (43 +/- 18 v 18 +/- 7%, P < .002). Five Cr patients decompensated during follow-up and had the worst CA shunts (76%, 66%, 51%, 48%, and 45%). Three subsequently received successful orthotopic liver transplantation, 1 died of hepatoma, and 1 is on the waiting list for transplantation. In conclusion, QLFTs define the degree of functional impairment in early cirrhosis and may identify Cr patients at greatest risk of decompensation who may require transplantation for survival.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9346731     DOI: 10.1002/lt.500030210

Source DB:  PubMed          Journal:  Liver Transpl Surg        ISSN: 1074-3022


  7 in total

1.  MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study.

Authors:  F Botta; E Giannini; P Romagnoli; A Fasoli; F Malfatti; B Chiarbonello; E Testa; D Risso; G Colla; R Testa
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

2.  Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.

Authors:  Nariné Baririan; Luc Van Obbergh; Jean-Pierre Desager; Roger K Verbeeck; Pierre Wallemacq; Peter Starkel; Yves Horsmans
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  Noninvasive assessment of liver function.

Authors:  Steve Helmke; Jordi Colmenero; Gregory T Everson
Journal:  Curr Opin Gastroenterol       Date:  2015-05       Impact factor: 3.287

4.  Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial.

Authors:  G T Everson; M L Shiffman; J C Hoefs; T R Morgan; R K Sterling; D A Wagner; J L Desanto; T M Curto; E C Wright
Journal:  Aliment Pharmacol Ther       Date:  2008-12-01       Impact factor: 8.171

5.  Predicting morbidity and mortality after hepatic resection in patients with hepatocellular carcinoma: the role of Model for End-Stage Liver Disease score.

Authors:  Kuang-Yu Hsu; Gar-Yang Chau; Wing-Yiu Lui; Shyh-Haw Tsay; Kuang-Liang King; Chew-Wun Wu
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

6.  Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality.

Authors:  Swee H Teh; John Christein; John Donohue; Florencia Que; Michael Kendrick; Michael Farnell; Stephen Cha; Patrick Kamath; Raymond Kim; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2005-12       Impact factor: 3.267

7.  Systemic vascular resistance in cirrhosis: a predictor of severity?

Authors:  Vinaya Gaduputi; Molham Abdulsamad; Sailaja Sakam; Naeem Abbas; Hassan Tariq; Ariyo Ihimoyan
Journal:  Hepat Med       Date:  2014-08-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.